Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2021 Dec 29;21(1):125–135.e8. doi: 10.1016/j.cgh.2021.12.038

Table 2.

IH staining grades and patterns in HBV-HIV Co-infected North American Adults at study entry and approximately 3–4 years later (N=56).

Baseline n (%) Follow-up n (%) Change P valuea
HBcAg staining grade, n (%) 0.058
 A (No positive hepatocytes) 21 (37.5) 35 (62.5)
 B (Less than 10% positive) 28 (50.0) 17 (30.4)
 C (≥10% positive) 7 (12.5) 4 (7.1)
HBcAg staining pattern 0.02
 No positive hepatocytes 21 (37.5) 35 (62.5)
 Only/predominately nuclear 20 (35.7) 13 (23.2)
 Only/predominately cytoplasmic 15 (26.8) 8 (14.3)
HBsAg staining grade, n (%) 0.63
 A (No positive hepatocytes) 13 (23.2) 16 (28.6)
 B (Less than 10% positive) 33 (58.9) 32 (57.1)
 C (≥10% positive) 10 (17.9) 8 (14.3)
HBsAg staining: Granular cytoplasmic- contiguous regions pattern 0.04
 No 36 (64.3) 45 (80.4)
 Yes 20 (35.7) 11 (19.6)
HBsAg staining pattern: Granular cytoplasmic-scattered hepatocytes b 0.44
 No 16 (28.6) 19 (33.9)
 Yes 40 (71.4) 37 (66.1)
HBsAg staining pattern: Inclusion-like b 0.03
 No 29 (51.8) 40 (71.4)
 Yes 27 (48.2) 16 (28.6)
HBsAg staining pattern: Membranous b 0.21
 No 45 (80.4) 49 (87.5)
 Yes 11 (19.6) 7 (12.5)
a

Changes were tested with mixed-effects models (binomial, ordinal logistic or multinomial, as appropriate) with a repeated outcome, time (i.e., days since first biopsy) as a continuous fixed effect, and random intercept. Median (IQR; range) of time between biopsies was: 3.6 (3.0–3.7; 2.6–4.1) years.